Introduction
Many of the currently used anticancer drugs are effective in killing proliferating cancer cells, but are less effective against nonproliferating cells that exist in the core of a solid tumour (Drewinko et al., 1981) . This presents a problem with residual disease, the quiescent cancer cells surviving the course of chemotherapy then presenting subsequently as relapse of the disease. The identification of new drugs or treatment modalities that circumvent this limitation would be an invaluable addition to the current arsenal available for the treatment of cancer.
Histone deacetylase inhibitors (HDIs) are a new class of drugs with anticancer potential. A number of these are now undergoing stage I/II clinical trial (Gabrielli et al., 2002; Marks et al., 2001) . These drugs have both cytostatic and cytotoxic activities, depending on the dose of drug used. At low doses, these drugs have cytostatic activity characterized by a G1 phase cell cycle arrest that is associated with the increased expression of the cyclin-dependent kinase (cdk) inhibitor p21 WAF1/CIP1 . The cytostatic activity of these drugs is not restricted to tumour cells, since normal cells also arrest in G1 phase (Qiu et al., 2000) . At higher doses, these drugs are selectively cytotoxic, killing a wide range of tumour and transformed cell lines but not normal cell lines (Qiu et al., 2000; Burgess et al., 2001) . We have shown that the selective cytotoxicity is a consequence of the functional status of an HDI-sensitive G2 phase cell cycle checkpoint. An intact checkpoint protects drugresistant cells, whereas drug-sensitive cells have a checkpoint defect (Qiu et al., 2000) . Activation of this checkpoint is only observed when drug-resistant cells are treated with high doses of drug that would be cytotoxic for drug-sensitive cells (Burgess et al., 2001; Richon et al., 2000) . Treatment of the majority of drug-sensitive cell lines with high doses of HDI kills a proportion of cells (20-50%) within 24 h, but also causes a G1 phase arrest in the surviving cells. These arrested cells still die, although the onset of cell death is slower than in cells that do not arrest in G1 (Burgess et al., 2001; Qiu et al., 2000) , suggesting that HDIs may be able to kill nonproliferating as well as proliferating cells. Other groups have reported that the leukaemic cell line CCRF-CEM engineered to inducibly express the cdk inhibitor p16 ink4a is refractory to the effects of HDI treatment when arrested in G1 phase by p16 ink4a induction (Bernhard et al., 1999; Peart et al., 2003) . This conflicting data prompted us to examine more closely the cytotoxicity of high-dose HDI treatment with nonproliferating cells to determine whether HDIs were capable of killing nonproliferating cells, and whether proliferating and nonproliferating cells were differentially sensitive to the cytotoxic effects of these drugs.
Results
To examine the HDI-hypersensitive cell line HaCaT, the observation that despite the G1 phase arrest induced in HDI-treated cultures, drug-sensitive cell lines continued to die (Burgess et al., 2001; Qiu et al., 2000) lead us to examine whether this class of drugs were also effective in killing nonproliferating cells. To examine this, the HDIhypersensitive cell line HaCaT (Burgess et al., 2001 ) was either grown continuously in 10% serum, or quiescent HaCaT cultures maintained in 0.1% serum for 4 days prior to and then throughout the experiment. Serum starvation resulted in a loss of proliferative activity in these cultures as measured by mitochondrial activity (Figure 1a ). When the cultures were treated with a cytotoxic dose of the HDI suberic bishydroxamic acid (SBHA; 10 mg/ml, D 50 5 mg/ml), proliferating cultures showed dramatic loss of viability as measured by their mitochondrial activity at 24 h after drug treatment and a complete loss of viability by 48 h. The serum-starved cells were less sensitive to drug treatment at 24 h compared to the proliferating cells, but there was a complete loss of viability at 48-72 h (Figure 1a) . Flow cytometric analysis of the drug-treated proliferating and serum-starved cultures revealed the reduced viability of the proliferating cultures, corresponding to an increase in the proportion of cells with subdiploid DNA content. This accumulation of subdiploid cells was reduced in the serum-starved cultures at 24 h, but by 48 h 490% of each population was subdiploid (Figure 1b) .
Immunoblotting of cell lysates revealed the presence of markers of apoptosis corresponding to the appearance of subdiploid cells and the loss of viability in both proliferating and serum starved cultures observed in Figure 1 . Caspase 3 cleavage, an indicator of its activation, was detected, as was cleavage of its substrate PARP. The BH3 only proapoptotic Bid protein was also cleaved and activated ( Figure 2 ). The protein levels of caspase 3 and Bid were reduced in the serum-starved cells compared to proliferating cultures when compared to the levels of PARP and a-tubulin. Although the cleavage of PARP, caspase 3 and Bid was detected in both proliferating and serum-starved cells at 24 h, the cleavage was more complete in the proliferating cells at this time, indicating a lower rate or later onset of cleavage in the serum-starved cells. There was also a strong increase in the level of cytosolic cytochrome c at 24 h after drug treatment, indicating disruption of the mitochondrial membrane, in both proliferating and serum-starved cells. In both cultures, there was a reduction in the levels of a-tubulin by 48 h after treatment, suggesting advanced proteolytic destruction of cells. The difference in the onset of apoptosis was not due to a difference in the efficacy of the drug under the different growth conditions, as drug produced similar levels of histone hyperacetylation in proliferating and quiescent cells (Figure 2 ). The growth status of cells had little effect on the dose response of SBHA. A small difference in the potency of the drug was observed after 48 h treatment, with the proliferating cultures being more sensitive, but this difference was negligible after 72 h treatment (Figure 3a) . The ability to kill both proliferating and nonproliferating cells was not a unique characteristic of SBHA but common to the four HDI tested, the related azelaic bishydroxamic acid (ABHA), which differs from SBHA by a single CH 2 unit in its carbon backbone, and the natural products Trichostatin A (TSA) and sodium butyrate (NaBu). When these drugs were used at doses equitoxic for proliferating HaCaT cells, they demonstrated a similar level of cytotoxicity to nonproliferating cells as measured by mitochondrial activity (Figure 3b) . Owing to the similar toxicity profiles of SBHA and ABHA, these drugs were used interchangeably throughout this study.
The ability of these drugs to induce apoptosis in both proliferating and nonproliferating cells suggested that the drugs were in some way targeting the mitochondrial membrane, possibly by inducing Bid cleavage, and the resulting cytochrome c release activating the apoptosome with the outcomes being the executioner caspase 3 activation. These events were observed in both drugtreated proliferating and quiescent cultures (Figure 2 ). To test this hypothesis, wild-type Bcl-2 or an inactive mutant was stably expressed in HaCaT cells, and the ability of SBHA to induce cell death and activation of components of the apoptotic machinery was examined. Only the data for the wild-type Bcl-2 transfected cells are shown as the inactive mutant Bcl-2-expressing cells behaved identically to the parental HaCaT cells. (data not shown). Expression of Bcl-2 had a protective effect on both proliferating and serum-starved cultures, although in both cases, a significant proportion of subdiploid cells were detected at 24 and 48 h after treatment (Figure 4a ). The accumulation of subdiploid cells was delayed in the Bcl-2-expressing cultures compared with mutant or parental controls, and rate of subdiploid accumulation was slower in the serumstarved compared to proliferating cultures, but by 72 h wild-type Bcl-2-expressing cultures contained 470% subdiploid cells independent of the initial growth status of the cultures. Examination of markers of apoptosis revealed reduced caspase 3 activation and PARP cleavage ( Figure 4c ) compared with proliferating cultures (Figure 2 ). There was also a delay in cytochrome c release after drug treatment, although this protection was lost by 48 h. Interestingly, Bid cleavage was little reduced in the wild-type Bcl-2-expressing cells compared with parental HaCaT cells (compare Bid cleavage in Figure 4c and Figure 2 ). Thus, Bcl-2 conveyed some protection, although the death signal initiated by HDI treatment eventually overcame the protective effect.
To ensure that the ability of HDI treatment to efficiently kill both proliferating and nonproliferating cells was not cell line or mechanism of arrest specific, a second cell line was used, the melanoma cell line SK-MEL-13 (ABHA D 50 50 mg/ml), which was engineered 1% media before treatment with the HDIs ABHA (100 mg/ml), SBHA (50 mg/ml), TSA (500 ng/ml) and NaBu (5 mM) for 48 h. Data is presented as a percentage of the untreated 48 h control, and are the mean and standard error from triplicate determinations . Two clones were tested and produced identical results, so data for only one is shown. The cells were induced with IPTG to express p16 ink4a for four days prior to drug addition, and IPTG was maintained throughout the experiment. IPTG induction of p16 ink4a resulted in a robust G1 arrest (Burgess et al., 2001 ). Two clones were tested and produced essentially identical results, so data for only one is shown. The cells were induced with IPTG to express p16 ink4a for 4 days prior to drug addition, and IPTG was maintained throughout the experiment. IPTG induction of p16 ink4a caused a strong cell cycle arrest with loss of S phase cells detected by 3 H-thymidine incorporation and flow cytometry (Figure 5a and b). Addition of 100 mg/ml SBHA or ABHA to the IPTGtreated, arrested cells resulted in a reduction in the amount of cell death after 24 h drug treatment compared to normally proliferating cultures, but by 48 h, there was little difference in proportion of subdiploid cells between the proliferating and arrested cultures ( Figure 5b ). By 72 h after treatment, essentially all cells were subdiploid. The onset of cell death was delayed during the initial 24 h of drug treatment, but by 48 h there was no significant difference between proliferating and nonproliferating cultures (Figure 5c ).
Examination of apoptotic markers revealed a high level of PARP and caspase 3 cleavage at 48 h after drug treatment ( Figure 6 ), corresponding to the rapid increase in cell death observed from 24-48 h after treatment in both proliferating and arrested cultures (Figure 5b and c). Bid cleavage was also not readily detected until 48 h, and only a very low level of cytosol cytochrome c was detected even at 48 h ( Figure 6 ). There was also a strong induction of p21 WAF1/CIP1 expression at 24 h as reported previously (Burgess et al., 2001) , although this level decreases at 48 h corresponding to activation of caspase 3. The levels of histone hyperacetylation after drug treatment was unaffected by the proliferative state of the cultures (Figure 6 ). The data from the two cell lines arrested in G0/G1 by different mechanisms demonstrated that HDIs were able to kill nonproliferating as well as proliferating cells, the major difference being the slower onset of cell death in the nonproliferating cells.
We have previously demonstrated that HDIs were selectively cytotoxic, with normal, nonimmortalized cell lines resistant to killing by even high doses of these drugs (Qiu et al., 2000; Burgess et al., 2001) . As these previous studies used proliferating cultures, we examined whether drug resistance was still observed in nonproliferating cells. Drug-resistant primary neonatal foreskin fibroblasts were serum starved for 4 days, , and then treated with 100 mg/ml ABHA or SBHA for a further 72 h. A small increase in the subdiploid population was observed in drug-treated cells grown in 10% serum, but in cells arrested in low serum this was further reduced (Figure 7a ). MTT analysis supported the flow cytometry data, demonstrating that the serumstarved cells were completely refractory to the HDIs over the 3 days treatment (Figure 7b) . Little difference was observed between the efficacy of the drug to induce histone hyperacetylation in proliferating and nonproliferating cultures (Figure 7c ). Previous studies have reported that p16 ink4a induced G0/G1 arrest in the leukaemic cell line CEM completely blocked the cell death induced by the HDI NaBu (Bernhard et al., 1999; Peart et al., 2003) . We failed to observe a similar effect of p16 ink4a induction in SK-MEL-13 cell lines. Therefore, we examined another cell line that expressed high constitutive levels of wild-type p16 ink4a , the melanoma cell line A2058. Treatment with 100 mg/ml SBHA resulted in only 11% cell death at 24 h and 44% cell death by 48 h. The rapid increase in cell death from 24-48 h corresponded to increased PARP, Bid, and caspase 3 cleavage at 48 h and increased cytosolic cytochrome c. The lack of cell death and apoptotic markers corresponded to a strong induction of p21
WAF1/CIP1 at 24 h, and its reduction at 48 h corresponded to increased apoptosis.
To determine whether loss of p21
was associated with apoptosis, we took advantage of the loss of attachment to culture plate that is associated with apoptosis to separately harvest the floating apoptotic cells and attached viable cells. The separate populations were analysed for apoptotic markers and p21 WAF1/CIP1 levels. Caspase 3 activation, PARP and Bid cleavage were only detected in the floating cells, and these cells contained no detectable p21WAF1/CI1, whereas strong p21 WAF1/CIP1 expression was detected in the attached cells (Figure 8c) . Thus, the delayed cell death observed appeared to correlate more strongly with HDI-increased p21 WAF1/CIP1 expression rather than p16 ink4a overexpression.
It has recently been reported that HDI-induced p21 WAF1/CIP1 expression is ATM dependent and can be inhibited with the ATM inhibitor caffeine (Ju and Muller, 2003) . SK-MEL-13 cells were treated with either 5 mM caffeine, or a sublethal dose of SBHA (50 mg/ml), or these drugs together, either with or without IPTG induction of p16 ink4a and cells harvested after 24 h SBHA treatment. Caffeine addition alone had no effect on cell death, and SBHA treatment caused only a modest (Figure 9a ). Induction of p16 ink4a had only a small effect on cell death. Caffeine was found to strongly inhibit HDI-induced p21 WAF1/CIP1 expression ( Figure 9b ). Caffeine treatment alone had little effect on apoptotic markers except for a decrease in caspase 3 levels (Figure 9b ), although this did not correspond to any PARP cleavage, indicating that it was a downregulation in its expression rather than cleavage. Caffeine did, however, synergise with SBHA to increase PARP and Bid cleavage (detected by the appearance of the Bid cleavage product). This was observed with proliferating SK-MEL-13 cultures and p16 ink4a -induced arrested cultures (Figure 9b) , and also in proliferating A2058 cultures (data not shown). Caffeine had no effect on SBHA-induced apoptosis in HaCaT cells that do not display increased p21 WAF1/CIP1 expression with HDI treatment, indicating that the synergizing effect of caffeine was due to the decreased p21 WAF1/CIP1 expression.
Discussion
Previous studies have examined the cytotoxicity of HDIs in proliferating cells. Our work has demonstrated that cytotoxicity was associated with the loss of an HDIsensitive G2 checkpoint. As a consequence, cells underwent an aberrant mitosis (Qiu et al., 2000) , and our recent studies have shown that the aberrant mitosis is a contributing factor to cell death. However, in a high proportion of cell lines treated with HDIs, there is a dramatic increase in expression of the cdk inhibitor p21 WAF1/CIP1 (Burgess et al., 2001; Sambucetti et al., 1999) . The consequence of the increased p21 WAF1/CIP1 expression is the rapid inhibition of cdk2/cyclin A and cdk2/cyclin E, loss of the hyperphosphorylated form of Rb and a block of entry into S phase (Archer et al., 1998; Sambucetti et al., 1999; Qiu et al., 2000) . Thus, treatment of asynchronous cultures with toxic doses of HDIs results in cell death in those cells that transit through mitosis in the presence of drug, whereas those cells that accumulate sufficiently high levels of p21 WAF1/CIP1 before entering S phase arrest at the G1/S phase boundary. This explains the loss of S and G2/M phase cells and the G1 arrest after 24 h HDI treatment in cell lines that have HDI-induced p21 WAF1/CIP1 expression (Burgess et al., 2001 ). However, we have consistently observed that with 48 and 72 h drug treatment even these G1-arrested cells appeared to die, suggesting that HDI treatment was also killing noncycling cells. In this study, we have arrested cells in G1 with extended serum starvation or induction of the cdk inhibitor p16
ink4a. These treatments resulted in a 490% reduction in the S phase population, and the arrest was maintained after HDI addition. HDI treatment also downregulates expression of cell cycle regulators such as cyclin B and cdc25C that are essential for mitotic progression, thus the aberrant mitotic pathway to apoptosis is not available for these G1-arrested cells (Qiu et al., 2000; Sambucetti et al., 1999) . The G1 phasearrested cells were dying while in G1 rather than escaping the arrest and continuing through to mitosis, then undergoing the cell death after aberrant mitosis. We have demonstrated that HDIs can be equally effective in killing proliferating and nonproliferating immortalized and tumour cells, but normal cells that are resistant to the cytotoxic effects of these drugs remain insensitive.
These findings confirm our previous observations with drug treatment of asynchronously growing cultures of over 30 immortalized and tumour cells lines. HDI treatment of the majority of the immortalized and tumour cells lines results in upregulated p21 WAF1/CIP1 expression and consequent G1 phase arrest. However, this did not protect these cells from the killing by the drug, although the onset of cell death was delayed (Burgess et al., 2001; Qiu et al., 2000) . Thus, the cytotoxicity of HDIs with nonproliferating cells is not restricted to the two drug-sensitive cell lines examined in this study, but is a general property of this class of drugs.
The major difference we have observed between HDItreated proliferating and arrested cells is the delayed onset of cell death in the arrested cells. In serum starved HaCaT cells, this is likely to be a consequence of the decreased expression of proapoptotic components cas- cleavage, under all conditions tested here. The exception was in the Bcl-2-overexpressing cells where significant Bid cleavage was observed at 24 h but increased cytosolic cytochrome c was not detected until 48 h, corresponding with dramatically increased cell death and apoptotic markers. This indicates that the apoptosis observed is dependent on mitochondrial disruption and cytochrome c release, and Bcl-2 protects the mitochondrial integrity by titrating out the activated Bid. Recent studies have shown that activation of Bid is necessary for HDI-induced apoptosis. Interestingly, p16 ink4a induction in the CEM cells also blocked Bid cleavage, correlating with resistance to killing (data not shown).
A number of studies have demonstrated that expression of cdk inhibitors such as p16 ink4a and p21
cause a G1 phase cell cycle arrest and protect cells against the cytotoxic actions of a range of conventional chemotherapeutic agents (Fueyo et al., 1998; Prabhu et al., 1999; Schmidt & Fan, 2001; Stone et al., 1996) . Two reports have demonstrated that p16 ink4a expression also blocked HDI-induced cell death in one cell line (Bernhard et al., 1999; Peart et al., 2003 are also susceptible to killing by HDIs. Thus, it appears that loss of HDI-sensitivity in p16 ink4a arrested CEM cells is a unique property of that cell line and not a general property of p16 ink4a expression or G1 phase-arrested cells. A possible explanation for the protective effect of p16 ink4a induction in the CEM cells is that p16 ink4a may compete with survivin for binding to cdk4, and that increased p16 ink4a expression results in the release of survivin from cdk4 complexes and a potential antiapoptotic effect. 21 WAF1/CIP1 can also directly inhibit apoptosis, and reducing HDI-induced p21 WAF1/CIP1 expression, either by inhibiting ATM with caffeine or by other means, increases the apoptosis induced by HDIs (Figure 10 ). Increased p21 WAF1/CIP1 expression mimics the effect of increased Bcl-2 expression, which also delayed the onset of apoptosis (Suzuki et al., 2000) .
This study demonstrates that HDIs are able to kill cells by two pathways, a rapid pathway that involves transit through the defective G2 checkpoint and undergoing an aberrant mitosis. The major difference we have observed between HDI-treated proliferating and arrested cells is the delayed onset of cell death in the arrested cells. In serum starved HaCaT cells, this is likely to be a consequence of the decreased expression of proapoptotic components caspase 3 and Bid. Caffeine treatment also decreased caspase 3 levels, although in that case increased apoptosis was observed suggesting that reduced Bid levels have a greater impact on the onset of apoptosis in serum-starved cells. Indeed, Bid cleavage and the appearance of cytosolic cytochrome c correlated with increased cell death and apoptotic markers, PARP and caspase 3 cleavage, in all cell lines and under all conditions tested here. The only exception was in the Bcl-2-overexpressing cells where significant Bid cleavage was observed at 24 h but increased cytosolic cytochrome c was not detected until 48 h, corresponding with dramatically increased cell death and apoptotic markers. This indicates that the apoptosis observed is dependent on mitochondrial disruption and cytochrome c release, and Bcl-2 protects the mitochondrial integrity by titrating out the activated Bid (Chittenden, 2002 ) and a slow pathway that is activated in G1 phase arrest cells. In cell lines that have HDIinduced p21 WAF1/CIP1 expression, only cells in late G1 and S phase, when exposed to HDIs, proceed through the aberrant mitosis and rapid apoptosis, whereas cells in G1 phase accumulate p21 WAF1/CIP1 and arrest. Both the rapid and slow death pathways are selective for immortalized and tumour cells, the selectivity in proliferating cells is dependent upon the functional status of the HDI-activated G2 phase cell cycle checkpoint. Recent studies have shown that activation of Bid is necessary for HDI-induced apoptosis (Henderson et al., 2003; Mitsiades et al., 2003; Ruefli et al., 2001) . The selectivity in the arrested cells appears to be identical to the proliferating cells, suggesting that same molecular defect could account for the selectivity in both cases. In proliferating cells, this is associated with loss of G2 checkpoint function, and in the G1-arrested cells some other as yet unknown role.
Here, we have previously demonstrated that HDIs have tumour-selective cytotoxicity. Interestingly, p16 ink4a induction in the CEM cells also blocked Bid cleavage, correlating with resistance to killing (data not shown).
This study demonstrates that HDIs are able to kill cells by two pathways, a rapid pathway that involves transit through the defective G2 checkpoint and undergoing an aberrant mitosis (Qiu et al., 2000) , and a slow pathway that is activated in G1 phase arrest cells. In cell lines that have HDI-induced p21 WAF1/CIP1 expression, only cells in late G1 and S phase, when exposed to HDIs, proceed through the aberrant mitosis and rapid apoptosis (Warrener et al., 2003) , whereas cells in G1 phase accumulate p21 WAF1/CIP1 and arrest. The arrest Figure 10 Model for the dual mechanisms of HDI-induced apoptosis. Exposure to toxic doses of HDIs during late G1 and S phase results in cells undergoing aberrant mitosis and rapid induction of apoptosis. Exposure to drug during G1 phase results in most cases in increased p21 WAF1/CIP1 expression and a G1 arrest. The G1 arrest delays the onset of apoptosis and p21 WAF1/CIP1 expression also inhibits the apoptotic mechanism, further delaying the onset of apoptosis Deacetylase inhibitors kill noncycling tumour cells A Burgess et al itself is responsible for the slower onset of apoptosis, but p21 WAF1/CIP1 can also directly inhibit apoptosis (Burgess et al., 2001; Suzuki et al., 1999) , and reducing HDIinduced p21 WAF1/CIP1 expression, either by inhibiting ATM with caffeine or by other means, increases the apoptosis induced by HDIs (Burgess et al., 2001; Rahmani et al., 2003; Rosato et al., 2001; Vrana et al., 1999) (Figure 10 ). Increased p21 WAF1/CIP1 expression mimics the effect of increased Bcl-2 expression, which also delayed the onset of apoptosis. Both the rapid and slow death pathways are selective for immortalized and tumour cells, the selectivity in proliferating cells is dependent upon the functional status of the HDIactivated G2 phase cell cycle checkpoint (Qiu et al., 2000) . The selectivity in the arrested cells appears to be identical to the proliferating cells, suggesting that same molecular defect could account for the selectivity in both cases. In proliferating cells, this is associated with loss of G2 checkpoint function, and in the G1-arrested cells some other as yet unknown role. The defect is likely to be a mechanism responding to the hyperacetylated state of the chromatin, which would account for the observed aberrant mitotic phenotype in proliferating cells (Taddei et al., 2001) . The consequences of hyperacetylated chromatin in G1-arrested cells may not be so rapidly apparent, accounting for the observed delay in onset of cell death.
The complete destruction of a tumour is the major goal of chemotherapy, but many of the commonly used drugs simply target the destruction of the proliferative fraction of cells within the body. This encompasses not only the tumour itself, but also proliferating stem cells populations in epithelial linings and immune system, resulting in the many undesirable toxicities associated with chemotherapy. The other problem with many of the chemotherapeutic drugs is that they are effective only against the proliferative fraction of the tumour, but in many solid tumours a high proportion of the tumour mass is not actively proliferating. Here, we have demonstrated that HDIs are cytotoxic to both proliferating and nonproliferating cells, with little loss of potency although there is a delay in the onset of cell death. We have previously demonstrated that HDIs have tumour-selective cytotoxicity (Qiu et al., 2000; Qiu et al., 1999) . Thus, this class of drugs has many of the characteristics desired in an anticancer drug, selective cytotoxicity and the ability to kill both actively proliferating and nonproliferating tumour cells. These attributes make this class of drugs ideal for treating not only highly proliferative tumours but also solid tumour that have a low proliferative index. HDIs have also been reported to possess antiangiogenic properties (Kim et al., 1999) , which is currently a primary focus for the destruction of solid tumours. Thus, these drugs are effective at multiple levels, targeting the destruction of only tumour cells, cytotoxic to both proliferating and arrested cancer cells and antiangiogenic. These properties indicate the potential utility of this class of drugs in the treatment of a wide range of malignancies.
Materials and methods

Materials
ABHA was synthesised as described previously (Parsons et al., 1997) . SBHA, TSA and NaBu were purchased from Sigma (St Louis, MO, USA). SAHA was a gift from Dr Victoria Richon (Aton Pharma, Tarrytown, NY, USA). All other chemicals used were of analytical grade.
Cell lines and culture conditions
The cell lines used were primary cultures of neonatal foreskin fibroblasts (NFF), a spontaneously immortalized keratinocyte (HaCaT), and two human melanoma cell lines, A2058 and SKMel-13, the latter was engineered for stable inducible expression of p16 ink4a , p16wt 4 and wt6 clones. The p16 ink4a open reading frame was cloned into pOPRSV of the Lac Switch system (Stratagene) to allow IPTG inducible expression of p16 ink4a . All cells were cultured in DMEM medium containing 0.1 mg/ml streptomycin, 100 U/ml penicillin, 3 mM 4-(2-hydroxyethyl) piperazineethane sulphonic acid (HEPES) and the indicated concentration of Serum Supreme (Biowhittaker). In addition, the p16 ink4a inducible lines were cultured with 400 mg/ ml Geneticin (Boehringer Mannheim, Germany) and 100 mg/ ml hygromycin (Gibco BRL, NY, USA) to maintain selection of the stable transfected cells. NFF and HaCaT cell lines were starved on 0.25 and 0.1% v/v serum, respectively, for 4 days with media replaced daily. The p16 ink4a inducible cell lines were cultured in 10% media with the addition of 5 mM IPTG to induce p16 ink4a expression for 4 days prior to treatment. Again media and IPTG were replaced daily to ensure maximum reduction in S phase cells. IPTG was maintained in the media after addition of HDIs to ensure continued expression of p16 ink4a . In addition, HaCaT cells were stably transfected with Bcl-2 wild type or inactive mutant (gifts from Dr David Huang, WEHI, Melbourne) and the stable transfectants were selected by puromycin selection. With serum starvation of HaCaT and NFF cell lines and the induction of p16 ink4a in SKMel-13 cells, the proportion of S phase cells was reduced to below 10% of controls as determined by either FACS, BrdU and or thymidine incorporation. Cells were treated with various doses of histone deacetylase inhibitors for 24-72 h. Assays for mycoplasma were carried out to ensure that the cultured cells were free of contamination.
Cell proliferation assay
Cells in log phase growth were seeded into 96-well plates at a density of 2-5 Â 10 3 on the day before treatment. Cells were then either starved for 4 days or exposed to various drugs for 24-72 h. Cell proliferation was measured using 3-(4,5-dimthylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St Louis, MO, USA), which measures mitochondrial activity of viable cells. MTT was added to the culture medium at a final concentration of 0.5 mg/ml, and the plated cells were incubated for 4 h at 371C. The insoluble formazan product was then precipitated by centrifuging the plates, removing the supernatant and redissolving the formazan crystals in 50 ml of DMSO. Absorbance at 570 nm was measured using a Mulitskan microplate reader (Labsystems, Helsinki, Finland).
Flow cytometry
For flow cytometric analysis, floating and attached cells were collected. Cells were fixed in ice-cold 70% ethanol and stored at À201C. Samples were then washed once in PBS and resuspended in a solution of propidium iodide (5 mg/ml) and RNase A (0.5 mg/ml) in PBS. The stained cells were filtered through a 37 mm gauze, and the single-cell suspensions were analysed on a FACSCalibur (Becton Dickinson, NJ, USA) using Cell Quest and Modfit data analysis software.
Immunoblotting
Cells were lysed in NETN buffer (100 mM NaCl, 1 mM EDTA, 0.5%. Nonidet P-40 and 20 mM Tris, pH 8) supplemented with 5 mg/ml aprotinin, 5 mg/ml pepstatin, 5 mg/ml leupentin, 0.5 mM phenylmethylsulphonyl fluoride, 10 mM sodium fluoride and 0.1 mM sodium orthovanadate. Samples (20 mg of protein) were resolved on a 12% SDS-PAGE and then transferred to 0.2 mM PVDF membranes (Amersham, England). For cytochrome c release assays, cells were permeablized with Digitonin buffer (20 mM HEPES pH 7.5, 10 mM KCl, 2.5 mM MgCl 2 , 1 mM EGTA, 250 mM sucrose, 200 mg/ml digitonin) with protease and phosphatase inhibitors added as above. Cell suspensions were centrifuged for 5 min and cytosolic fraction was removed for cytochrome c release by immunoblotting. Samples were immunoblotted with antibodies against acetyl lysine, acetylated histone H4, cytochrome c and Bid (Cell Signaling), caspase 3, p21 WAF1/CIP1 and PARP (BD Clontech), a-tubulin (Sigma-Aldrich) and p16 ink4a (Wang et al., 1996) using the appropriate horseradish peroxidase-conjugated secondary antibody (Zymed) and enhanced chemiluminescence (New England Nuclear, Boston, MA, USA) detection.
Thymidine incorporation assay
Cells were seeded into 12-well plates on the day prior to treatment.
3 H-thymidine (Amersham) was added at a final concentration of 2.5 mCi/ml, and incubated with cells for 3 h at 371C. Cells were then washed three times with ice-cold PBS, and then fixed with 90% ethanol, 5% acetic acid and 5% H 2 O, and then stored at 41C. Cells were lysed in 200 ml of 0.5 M NaOH for 5-15 min at 371C. An equal volume of 1 M HCl was added to each well and 200 ml of sample was added to10 ml of aqueous scintillant and samples were quantitated by scintillation counting. Bradford protein estimations were run on each sample and luminescence was corrected accordingly.
